文献速递颈动脉与弓上血管

无症状颈动脉狭窄患者最佳药物治疗下5年生存评分的建立:Carotid Asymptomatic Stenosis研究结果

A score system to determine the 5-year survival in patients with asymptomatic carotid stenosis under best medical therapy: Results from the Carotid Asymptomatic Stenosis study.
PubMed 文献 · J Vasc Surg · 2026-06-13

该前瞻性观察性队列研究纳入307例无症状颈动脉狭窄>60%且未行血运重建的患者,评估最佳药物治疗下的长期生存。结果显示5年总生存率为80±2%,年龄、糖尿病、慢性肾脏病和冠心病是独立死亡预测因子,基于这些变量建立的评分可识别高危患者。

要点

  • 5年总生存率为80±2%,≤80岁为90±2%,81-85岁为75±4%,>85岁为67±6%。
  • 糖尿病、慢性肾脏病、冠心病和年龄是独立死亡预测因子。
  • 评分>3分者5年生存率仅52%,显著低于≤3分者的87%。

核心结论

  • 在最佳药物治疗下,无症状颈动脉狭窄患者的5年生存率较高,且更多由合并症而非单纯高龄驱动。

研究设计与样本

  • 前瞻性观察性队列研究(NCT04825080),纳入307例无症状颈动脉狭窄>60%的患者,平均年龄80±7岁,55%为男性。

主要发现

  • 总体5年生存率为80±2%,≤80岁、81-85岁和>85岁患者分别为90±2%、75±4%和67±6%(P < .001)。
  • 多变量Cox回归显示糖尿病(HR 2.2,95%CI 1.5-3.3,P < .001)、慢性肾脏病(HR 2.2,95%CI 1.3-3.8,P < .001)、冠心病(HR 2.0,95%CI 1.3-3.0,P < .001)、年龄81-85岁(HR 2.5,95%CI 1.5-4.1,P < .001)和年龄>85岁(HR 3.5,95%CI 2.1-5.8,P < .001)是独立死亡预测因子。
  • 评分>3分者5年生存率为52%,显著低于评分≤3分者的87%(P < .001)。

关键数值与推荐

  • 死亡风险评分:糖尿病、慢性肾脏病、冠心病、年龄81-85岁各1分,年龄>85岁2分。
  • 评分≥3分对高危患者具有高特异性(AUC 75%)。

临床怎么用

  • 该评分可用于无症状颈动脉狭窄患者在接受颈动脉血运重建前的风险分层,帮助识别可能从手术中获益有限的高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current international guidelines do not recommend carotid revascularization in patients with asymptomatic carotid artery stenosis (ACAS) with a life expectancy less than 5 years or high-risk clinical conditions. However, improvements in medical therapy leading to a reduction of cerebral ischemic events risk may improve long-term survival. After a previous report of 5-year cerebral ischemic event outcomes in a prospective observational study of patients with ACAS treated with best medical therapy (BMT), the long-term survival in the same population was evaluated. METHODS: This was a prospective (NCT04825080; Carotid Asymptomatic Stenosis Study) observational cohort study including patients with ACAS > 60% (North American Symptomatic Carotid Endarterectomy Trial criteria) started in 2019 and ended in 2025. Patients were not considered for carotid revascularization due to high surgical risk or the absence of plaque vulnerability features. BMT was defined as regular intake of antiplatelet therapy and statins, blood pressure control, and cessation/absence of smoking. Follow-up included annual clinical visits and 6-month telephone interviews. The primary endpoint was overall survival, stratified by age (≤80, 81-85, and >85 years). Secondary analyses aimed to identify independent predictors of mortality and to develop a mortality risk score. RESULTS: A total of 307 patients were included (mean age, 80 ± 7 years; 55% male). Contralateral carotid stenosis > 60% was present in 61 patients (20%). At the end of follow-up, 86% of patients were under BMT. The overall transient ischemic attack /stroke rate was 1.3% per year, with higher risk for contralateral stenosis (1.9%) and plaque progression (1.8%). The overall 5-year survival rate was 80 ± 2%, with age-related differences: 90 ± 2% in patients ≤ 80 years, 75 ± 4% in those aged 81 to 85 years and 67 ± 6% in patients > 85 years (P < .001). Multivariable Cox regression identified diabetes mellitus [hazard ratio (HR), 2.2; 95% confidence interval (CI), 1.5-3.3; P < .001), chronic kidney disease (HR, 2.2; 95% CI, 1.3-3.8; P < .001), coronary artery disease (HR, 2.0; 95% CI, 1.3-3.0; P < .001), age 81 to 85 years (HR, 2.5; 95% CI, 1.5-4.1; P < .001), and age >85 years (HR, 3.5; 95% CI, 2.1-5.8; P < .001) as independent predictors of mortality. Based on these variables, a mortality score was developed: one point each for diabetes mellitus, chronic kidney disease, coronary artery disease, and age 81 to 85 years, and two points for age >85 years. Receiver-operating characteristic curve analysis identified a score ≥ 3 as highly specific for patients at high risk (area under the curve, 75%). Patients with a score > 3 had significantly lower 5-year survival (52%) compared with those with a score ≤3 (87%; P < .001). CONCLUSIONS: In patients with ACAS under BMT, 5-year survival is high, and it is driven more by comorbid clinical conditions than by advanced age alone. These findings may help refine patient selection and risk stratification when considering carotid revascularization.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lodato M, Pini R, Rocchi C, et al. A score system to determine the 5-year survival in patients with asymptomatic carotid stenosis under best medical therapy: Results from the Carotid Asymptomatic Stenosis study. J Vasc Surg. 2026. PMID: 42285186. doi:10.1016/j.jvs.2026.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。